



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	338074	MolyZinc
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Interclinical Laboratories Pty Ltd	
<b>Postal Address</b>	PO Box 6474, ALEXANDRIA, NSW, 2015 Australia	
<b>ARTG Start Date</b>	18/06/2020	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . MolyZinc

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	18/06/2020
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Maintain/support collagen formation  
Maintain/support energy levels  
Maintain/support healthy eye function  
Maintain/support eye health  
Maintain/support healthy eyesight/vision  
Maintain/support general health and wellbeing  
Maintain/support hair health  
Maintain/support healthy teeth  
Maintain/support nail health/strength/thickness  
Maintain/support connective tissue health  
Aid/assist/helps connective tissue production/formation  
Maintain/support bone health  
Aid/assist healthy red blood cell production  
Helps maintain/support haemoglobin formation/synthesis  
Maintain/support blood capillary health  
Maintain/support blood vessel health  
Maintain/support immune system health  
Maintain/support healthy immune system function  
Aid/assist/helps protein synthesis in the body  
Maintain/support absorption of dietary (state vitamin/mineral/nutrient)  
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency  
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)

Public Summary



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

Maintain/support cognitive function/mental function in healthy adults  
 Maintain/support nerve conduction  
 Aid/assist/helps synthesis of neurotransmitters  
 Maintain/support nervous system health  
 Maintain/support nervous system function  
 Maintain/support female reproductive system health  
 Maintain/support preconception health in healthy males  
 Maintain/support preconception health in healthy females  
 Maintain/support reproductive system health in males  
 Maintain/support healthy reproductive hormones  
 Maintain/support sperm health in healthy males  
 Maintain/support sperm production in healthy males  
 Maintain/support testosterone level  
 Maintain/support skin health  
 Maintain/support skin integrity/structure  
 Maintain/support skin regeneration  
 Maintain/support wound healing

**Indication Requirements**

Product presentation must not imply or refer to mental illnesses, disorders or conditions.  
 Product presentation must not imply or refer to hormone imbalances.  
 Product presentation must not imply or refer to serious cardiovascular conditions.  
 Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).  
 Label statement: If symptoms persist, talk to your health professional.  
 Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.  
 Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.  
 Product presentation must not imply or refer to infertility.  
 Product presentation must not imply or refer to chronic fatigue syndrome.  
 Product presentation must not imply or refer to serious immunological diseases.  
 If directed to women, Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

**Additional Product information**

**Pack Size/Poison information**

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

**Components**

**1 . Formulation 1**

<b>Dosage Form</b>	Capsule, hard
<b>Route of Administration</b>	Oral

**Visual Identification**

**Active Ingredients**

ascorbic acid	30 mg
molybdenum trioxide	150 microgram
Equivalent: molybdenum	100 microgram

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

<b>pyridoxal 5-phosphate monohydrate</b>	<b>1.61 mg</b>
Equivalent: pyridoxine	1.03 mg
<b>zinc glycinate monohydrate</b>	<b>17.7 mg</b>
Equivalent: zinc	5 mg

**Other Ingredients (Excipients)**

calcium hydrogen phosphate dihydrate  
colloidal anhydrous silica  
hypromellose  
magnesium stearate  
microcrystalline cellulose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary